NCT05017142 is a clinical trial in Optic Neuritis, sponsored by University of Bern.

Who is sponsoring NCT05017142?

NCT05017142 is sponsored by University of Bern.

What condition does NCT05017142 study?

NCT05017142 studies Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Anti-NMDAR Encephalitis, Anti-GAD65 Associated Autoimmune Encephalitis, Anti-AMPAR-1/2 Associated Autoimmune Encephalitis, Anti-Lgi-1 Associated Autoimmune Encephalitis, Anti-CASPR-2 Associated Autoimmune Encephalitis, Anti-GABAR-1/2 Associated Autoimmune Encephalitis, Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis, Hashimoto Encephalitis, CNS Vasculitis, CNS Sarcoidosis, CNS Lupus, Rasmussen Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Is NCT05017142 still recruiting?

NCT05017142 is currently recruiting now. Last updated 16 December 2024.

Last reviewed 2024-12-16 · How we verify

NCT05017142

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Recruiting now Last updated 16 December 2024

What this trial tests

trial in Optic Neuritis in 500 participants. Currently enrolling.

Timeline

14 April 2020

Primary endpoint
1 January 2071

1 January 2071

Quick facts

Lead sponsor	University of Bern
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	500
Start date	14 April 2020
Primary completion	1 January 2071
Estimated completion	1 January 2071
Sites	13 locations across Switzerland

Conditions studied

Optic Neuritis — all drugs for Optic Neuritis →
Transverse Myelitis — all drugs for Transverse Myelitis →
Acute Disseminated Encephalomyelitis — all drugs for Acute Disseminated Encephalomyelitis →
Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

University of Bern

Who can join

Under 36, any sex, with Optic Neuritis or Transverse Myelitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur and Zurich. The center in Fribourg is expected open for recruitment in 2025. The registry provides data for national and international monitoring and research. It supports research on inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians, researchers, and therapists. The registry aims to improve the treatment of children with inflammatory brain diseases and optimizing their health care and quality of life.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Human retinal secretome: A cross-link between mesenchymal and retinal cells.
Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665
Medical Applications of Molecular Biotechnologies in the Context of Hashimoto's Thyroiditis.
Trovato M, Valenti A. · · 2023 · cited 1× · PMID 37371008 · DOI 10.3390/diagnostics13122114
Functional roles and clinical potential of SOX1 in cancer as a biomarker and therapeutic target.
Zhou X, Wang J, Yang F, Gao Y, et al · · 2026 · PMID 41931180 · DOI 10.1007/s12672-026-04431-4

Verify or expand the search:

Other recruiting trials for Optic Neuritis

Currently open trials in the same condition.

NCT07100990 — Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) · Phase 3 · recruiting
NCT06389968 — Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis · NA · recruiting
NCT05487989 — VIsual Pathways Model in Neuro-inflammatory Disorders · recruiting
NCT05540262 — Edaravone in the Treatment of Optic Neuritis · NA · recruiting

Other University of Bern trials

Trials by the same sponsor.

NCT05940662 — Cost Effectiveness of Various Implant Placement Protocols in the Esthetic Zone · Phase 4 · suspended
NCT02919163 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7) · NA · not yet recruiting
NCT02919189 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7) · NA · not yet recruiting
NCT04817592 — Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive · not yet recruiting
NCT06806150 — The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05017142 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Bern
Last refreshed: 16 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05017142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing